Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lansoprazole
Drug ID BADD_D01245
Description Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]
Indications and Usage For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Marketing Status Prescription; OTC; Discontinued
ATC Code A02BC03
DrugBank ID DB00448
KEGG ID D00355
MeSH ID D064747
PubChem ID 3883
TTD Drug ID D06YYD
NDC Product Code 60687-111; 0113-7116; 68788-6390; 71335-0575; 38779-2289; 71335-0043; 0363-4069; 65015-658; 46122-698; 65628-080; 64764-046; 0093-7350; 11532-1441; 49035-373; 53104-7526; 62175-415; 72288-343; 52932-0730; 11673-117; 70700-263; 66332-1443; 0093-3009; 64679-140; 0904-6662; 55111-044; 64679-669; 49452-3041; 43598-560; 41520-816; 67877-275; 63629-2342; 59779-117; 67877-274; 11532-1440; 63629-4851; 68071-3019; 55111-399; 69256-401; 50090-4596; 50090-5180; 42291-433; 31722-571; 49348-301; 30142-288; 49711-0110; 0378-8015; 72288-829; 0113-0116; 68071-4456; 68382-772; 41250-391; 72288-301; 51838-123; 70700-262; 42765-023; 72476-020; 70771-1132; 68788-7742; 0378-8030; 0536-1324; 41250-117; 70677-0124; 31722-570; 59349-0015; 0536-1236; 63629-7552; 64764-541; 68071-5119; 63739-555; 71335-0917; 71052-242; 62175-430; 62756-252; 61919-890; 51927-3877; 68382-771; 68071-2274; 68001-111; 60687-123; 65841-770; 41163-117; 63981-582; 11822-0117; 62011-0472; 63187-510; 11822-3374; 69842-270; 62175-515; 70000-0508; 0781-2148; 0113-6002; 55154-0253; 63629-2340; 50090-2225; 55289-704; 56062-283; 27241-020; 36800-392; 0113-0117; 30142-117; 70771-1133; 72189-279; 71335-1820; 49035-739; 71335-1425; 79903-068; 27241-019; 0363-0739; 52562-021; 43598-561; 55111-739; 68788-7789; 30142-192; 63415-0060; 65372-1136; 63187-152; 45865-879; 45802-878; 65977-0013; 11673-280; 56062-117; 69842-755; 0781-2147; 50090-3195; 37012-117; 43598-883; 0067-6286; 16714-186; 62011-0168; 66332-1442; 42291-365; 51079-121; 68391-117; 80425-0174; 63850-3309; 63629-2341; 55910-117; 68001-112; 16571-698; 0378-6981; 63868-429; 0378-6982; 71335-1521; 46122-107; 16714-185; 64764-543; 16571-697; 36800-295; 51552-1239; 64764-544; 51927-0064; 0093-3008; 21130-181; 55154-4848; 57896-761; 63981-117; 42291-364; 55910-307; 45802-245; 69842-507; 64679-670; 16571-742; 68382-543; 0363-1419; 81522-001; 70000-0069; 68016-758; 80425-0148; 68382-544; 70756-806; 70756-807; 0113-1114; 0093-7351; 71335-0058; 42291-434; 41163-150; 68788-7385; 0378-3995; 51407-324; 65841-769; 49035-411; 72189-062; 37808-755; 64374-007; 0113-7003; 55111-398; 61919-245; 61919-655; 0363-1212; 60760-544; 36800-117; 71335-0105
Synonyms Lansoprazole | Lansoprazol | 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole | Lansoprazoles | Ogastro | AG 1749 | AG-1749 | AG1749 | Agopton | Bamalite | Lansol | Lansoprazole Sodium | Sodium, Lansoprazole | Lanzor | Monolitum | Opiren | Prevacid | Pro Ulco | Promeco | Takepron | Ulpax | Zoton | Ogast | Prezal
Chemical Information
Molecular Formula C16H14F3N3O2S
CAS Registry Number 103577-45-3
SMILES CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sensation of foreign body08.01.09.0020.001676%Not Available
Vocal cord disorder22.04.01.0030.000419%Not Available
Blood disorder01.05.01.0040.000629%Not Available
Gastrointestinal malformation07.11.04.004; 03.04.07.002--Not Available
Respiratory syncytial virus infection22.07.02.002; 11.05.13.0010.000419%Not Available
Blood electrolytes decreased13.11.02.007--Not Available
Blood electrolytes increased13.11.02.008--Not Available
Disease recurrence08.01.03.0500.000838%Not Available
Drug intolerance08.06.01.013--Not Available
Occult blood positive13.05.02.001--Not Available
Psychotic disorder19.03.01.002--
Gastric neoplasm16.13.11.003; 07.21.04.006--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.010--Not Available
Congenital genitourinary abnormality21.15.02.002; 20.08.03.001; 03.06.02.002--Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.010--
Chronic kidney disease20.01.03.0170.007597%
Substance abuse19.07.02.0060.000419%Not Available
Mixed liver injury09.01.07.0150.000419%Not Available
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.0220.000838%Not Available
Regurgitation07.01.07.0040.000838%Not Available
Cholestatic liver injury09.01.07.0160.001467%Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.003562%
Acute kidney injury20.01.03.0160.012990%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.003143%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 23.03.05.0050.006495%Not Available
Medication residue present13.15.01.0320.000419%Not Available
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages